Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 9/20 | 0.54 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406964 | 0.95 | PPARG (0.56) | L3MBTL1PPARGLTB4RPPARDPPARA | |
| SCHEMBL9716918 | 0.94 | MEN1 (0.57) | L3MBTL1PPARGLTB4RPPARDPPARA | |
| SCHEMBL10803242 | 0.94 | MEN1 (0.57) | L3MBTL1PPARGLTB4RPPARDPPARA | |
| SCHEMBL8081126 | 0.94 | MEN1 (0.57) | L3MBTL1PPARGLTB4RPPARDPPARA | |
| SCHEMBL8081517 | 0.94 | MEN1 (0.57) | L3MBTL1PPARGLTB4RPPARDPPARA | |
| SCHEMBL8080247 | 0.94 | MEN1 (0.57) | L3MBTL1PPARGLTB4RPPARDPPARA | |
| SCHEMBL8072236 | 0.94 | MEN1 (0.57) | L3MBTL1PPARGLTB4RPPARDPPARA | |
| SCHEMBL8081501 | 0.94 | MEN1 (0.57) | L3MBTL1PPARGLTB4RPPARDPPARA | |
| SCHEMBL8084869 | 0.92 | L3MBTL1 (0.57) | L3MBTL1PPARGLTB4RPPARDPPARA | |
| SCHEMBL2982851 | 0.86 | L3MBTL1 (0.54) | L3MBTL1LTB4RPPARDNPSR1LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2012168458-A1 | ZWITTERIONIC COMPOUNDS USEFUL AS CATALYSTS FOR ESTERIFICATION REACTIONS AND PROCESSES FOR THEIR PRODUCTION | ECOSYNTH BVBA (BE) | 2012-12-13 | — | — | WO | disclosed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | CANNIZZARO CARINA | 2009-09-10 | — | — | US | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7427624-B2 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| CN-1780822-A | Use of derivatives of 2, 4-dihydro- 1,2,4 triazole-3-thione as inhibitors of the enzyme myeloperoxidase (MPO) | ASTRAZENECA AB (SE) | 2006-05-31 | — | — | CN | disclosed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005108374-A1 | INSECTICIDAL DIAZOLE AND TRIAZOLE DERIVATIVES | FMC CORPORATION (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
| EP-0758013-B1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL CO LTD (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | PHOSPHO1, NFATC1, IFNG | L3MBTL1 4611/4885PPARG 1382/4885LTB4R 423/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | L3MBTL1 4852/4885PPARG 231/4885LTB4R 40/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | L3MBTL1 2594/4885PPARG 1470/4885LTB4R 4109/4885 |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | L3MBTL1 3772/4885PPARG 987/4885LTB4R 719/4885 |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | PNP, TYMP, MTAP | L3MBTL1 3935/4885PPARG 3046/4885LTB4R 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.